[EN] SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS<br/>[FR] COMPOSÉS DE SULFONAMIDE HÉTÉROCYCLIQUES SUBSTITUÉS UTILES COMME MODULATEURS DE TRPA1
申请人:HOFFMANN LA ROCHE
公开号:WO2015052264A1
公开(公告)日:2015-04-16
The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
Iridium-Catalyzed Site-Selective C–H Borylation of 2-Pyridones
作者:Koji Hirano、Masahiro Miura、Wataru Miura
DOI:10.1055/s-0036-1588735
日期:2017.11
An iridium-catalyzed site-selective C–H borylation of 2-pyridones has been developed. The site selectivity is predominantly controlled by steric factors, and we can access C4, C5, and C6 C–H on the 2-pyridone ring by the judicious choice of ligand and solvent. Subsequent Suzuki–Miyaura cross-coupling of the borylated products also proceeds to form the corresponding arylated pyridones in good overall
HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME
申请人:Sumitomo Chemical Company, Limited
公开号:US20190327970A1
公开(公告)日:2019-10-31
A heterocyclic compound that exhibits superior control effects against harmful arthropods is provided. In particular, a heterocyclic compound of formula (I) is provided, wherein the variable groups are as defined in the specification. Also provided is a composition containing the heterocyclic compound of formula (I) and one or more types of components selected from the components described in the specification.
SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
申请人:Genentech, Inc.
公开号:US20160221945A1
公开(公告)日:2016-08-04
The invention is concerned with the compounds of formula I or II:
and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.